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Epilepsy is a chronic neurologic disorder that
affects people of all ages, approximately 50 million
worldwide, or about 0.7% of the population.
Patients with epilepsy suffer from recurrent
seizures, which can be focal or generalized in
nature. Generalized seizures involve both cerebral
hemispheres simultaneously, whereas focal seizures
start as a specific focus in the brain, but they may be
also secondarily generalized (called ëfocal to bilater-
al tonic-clonic seizuresí). The new classification of
seizure types and classification of epilepsies have
been announced by the ILAE (International League
Against Epilepsy) in 2017. Epilepsy is defined as
having 2 or more unprovoked seizures. One seizure
does not signify epilepsy (up to 10% of people
worldwide have one seizure during their lifetime)
(1, 2). However, epilepsy can also be diagnosed
after one unprovoked seizure if additional data sug-
gest that the risk of recurrent seizure is high (3).
As the first line of treatment, antiepilep-
tic drugs (AEDs) are routinely used to control
seizures.
AEDs treat the symptoms (seizures) but not the
cause of epilepsy, there is no drug that inhibits the
processes of epileptogenesis (4). There are currently
three generations of AEDs (Table 1). The first-gen-
eration of AEDs were developed as early as 1912
(phenobarbital) through the 1970s. The first of the
second-generation drugs, felbamate, was approved
in 1993. The overall aim of developing newer AEDs
is better efficacy, more favorable pharmacokinetics
and fewer undesirable effects in comparison to the
first-generation drugs. However, there are a lot of
examples of the limitations of the second-generation
anticonvulsant drugs, like Steven-Johnson syn-
drome with lamotrigine, cognitive impairment with
topiramate, kidney stones with zonisamide and top-
iramate, encephalopathy and non-convulsive status
epilepticus with tiagabine, life-threatening aplastic
anemia or hepatic failure with felbamate. Moreover,
not all of the second-generation drugs have favor-
able pharmacokinetics. An example might be felba-
mate, which is an inhibitor of CYP2C19 and
CYP1A2, thus inhibiting the metabolism of several
others AEDs. On the other hand, among the second-
generation drugs, levetiracetam is an example of the
drug with high oral availability (almost 100%), lin-
ear pharmacokinetics, minimal protein binding
(< 10%), no metabolism through P450 enzymes, and
renal elimination (95% of the dose).
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including the third-generation of anticonvulsant drugs. Additionally, the occurrence of adverse drug effects is
responsible for poor compliance as well as discontinuation of the therapy, in up to 25% of patients before hav-
ing reached the effective dose amount. Neuropsychiatric undesirable effects include depression, aggression,
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ideation and behavior have been reported in patients treated with anticonvulsant drugs.
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Third-generation anticonvulsant drugs
The third-generation of AEDs begins in 2008
with the approval of lacosamide in Europe and the
United States (3). It includes also rufinamide, viga-
batrin, retigabine, perampanel, eslicarbazepine
acetate, brivaracetam, and stiripentol.
Lacosamide
Lacosamide (R-2-acetamido-N-benzyl-3-meth-
oxypropionamide) a chiral functionalized amino acid
molecule is an anticonvulsant drug with a unique
mode of action, selectively enhancing slow inactiva-
tion of voltage-gated sodium channels (5). It is
thought that slow inactivation may involve rearrange-
ment of the inner pore structure of sodium channels,
while fast inactivation is mediated by an intracellular
peptide loop located between domains III-IV (4).
Moreover, lacosamide is the first drug for which an
interaction with the collapsin response mediator pro-
tein-2 (CRMP-2) has been described. This phospho-
protein, mainly expressed in the nervous system, is
involved in neuronal differentiation and axonal
growth. It has been reported, that the decrease of
CRMP-2 may contribute to the pathomechanisms
involved in temporal lobe epilepsy (6). The nature of
the interaction between lacosamide and CRMP-2 is
not completely known, it may directly bind with
CRMP-2 or act by an indirect functional interaction
with CRMP-2 (4). Chemically lacosamide is (R)-
enantiomer, and it is at least 100 times more potent in
seizure models compared to the (S)-enantiomer (Less
et al., 2006). Lacosamide was approved as monother-
apy or adjunctive therapy in adults (≥ 17 years) with
partial-onset (focal) seizures in the United States, and
as adjunctive treatment of partial-onset seizures with
or without secondary generalization in patients with
epilepsy, age 16 and over in the EU (7, 8). Currently,
in the EU it is indicated as monotherapy and adjunc-
tive therapy in the treatment of partial-onset seizures
with or without secondary generalization in adults,
adolescents and children from 4 years of age with
epilepsy. Lacosamide is available in oral and intra-
venous forms with a maximum daily dose of 400 mg,
divided twice daily (3). At doses > 400 mg/d, patients
with known cardiac conduction disorders, severe
heart disease, and parallel PR prolongation therapy
should be carefully observed. 
The pharmacokinetic properties of lacosamide
include almost 100% bioavailability, biding with
protein < 15%, a half-life of approximately 13 h,
minimal cytochrome P450 interaction and excretion
by the kidneys (unchanged about 40% of the dose,
the remainder in the form of metabolites).
Lacosamide has limited interactions with a range of
other AEDs.
Common undesirable effects include dizziness,
diplopia, headache, fatigue, nausea, and vomiting.
Dizziness was reported in approximately 30% of
patients and was the primary reason for discontinu-
ation from clinical trials (9).
The efficacy and safety of adjunctive
lacosamide have been demonstrated in randomized
placebo-controlled trials that recruited patients with
uncontrolled partial seizures (10, 11). Currently this
drug, as well as the other second-line drugs, such as
levetiracetam, topiramate, or pregabalin have been
increasingly used for the treatment of status epilep-
Table 1. Anticonvulsant drugs.
Specific anticonvulsant drugs
First-generation Second-generation Third-generation
Valproic acid Felbamate Lacosamide
Carbamazepine Lamotrigine Rufinamide
Phenytoin Tiagabine Vigabatrin
Ethosuximide Topiramat Ezogabine (retigabine)
Phenobarbital Levetiracetam Perampanel
Primidone Oxcarbazepine Eslicarbazepine acetate
Gabapentin Brivaracetam
Pregabalin Stiripentol
Zonisamide
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ticus in humans (off-label use) (12, 13). Recently, it
has been demonstrated in a multicenter open-label
trial that lacosamide is efficacious and well-tolerat-
ed by the treated patients with uncontrolled partial-
onset seizures as first add-on treatment at doses of
300-400 mg/day, which means that it can be added
as a first adjunctive drug after a first monotherapy
(14). Furthermore, other studies showed, that long-
term therapies with lacosamide, both as monothera-
py and as adjunctive treatment were efficient, gener-
ally well tolerated, with good safety profile (7, 15,
16). It seems to be a valued option for patients with
focal epilepsy. 
Lacosamide was also evaluated for the treat-
ment of peripheral diabetic neuropathy initially with
positive outcomes (17-19), however, recently its
limited efficacy in this condition, even at higher
doses has been reported (20, 21). Analgesic efficacy
of lacosamide has not been adequately proved in any
other neuralgia, and it is not licensed for the treat-
ment of any painful conditions.
Rufinamide 
Rufinamide (1-[(2,6-difluorophenyl) methyl]-
1H-1,2,3-triazole-4 carboxamide) is a triazole deriv-
ative structurally unrelated to other AEDs. The
mechanism of action of rufinamide is modulation of
activity in sodium channels, particularly prolonga-
tion of the inactive state, resulting in a decrease of
frequency of sustained repetitive firing (22). In the
in vitro, studies rufinamide at 1 µmol/L or higher
significantly slowed sodium channel recovery from
inactivation after a prolonged prepulse in cultured
cortical neurons from immature rats. It limited sus-
tained repetitive firing of sodium-dependent action
potentials, with an EC50 of 3.8 µmol/L (23). 
Rufinamide is approved for adjunctive treat-
ment for children 4 years and older and adults with
Lennox-Gastaut syndrome (childhood drug-resistant
epilepsy, with intellectual dysfunction and particular
EEG abnormalities). In particular, it has shown ade-
quate ef?cacy against tonic and atonic seizures (24).
Rufinamide is available in oral form with a maxi-
mum daily dose of 3200 mg, divided twice daily.
The pharmacokinetic properties include > 85%
bioavailability, time to peak blood levels of 4-6 h,
up to 35% protein bound, a half-life of 6-10 h.
Rufinamide metabolism does not involve isoen-
zymes of the cytochrome P450. The main metabolic
pathway is hydrolysis of the carboxyl-amidic group
with the production of inactive metabolites which
are eliminated through renal excretion (70%).
Rufinamide levels can be modified by the concomi-
tant administration of other AEDs. Valproic acid
increases the plasma concentration of rufinamide up
to 70%, whereas phenytoin, phenobarbital, and less
carbamazepine can decrease levels by up to 40-50%.
The efficacy of rufinamide in the treatment of
Lennox-Gastaut syndrome, adult and pediatric focal
seizures, and other epilepsy syndromes has been
established through clinical trials (22, 25-27).
Common adverse effects involved somnolence,
fatigue, poor appetite, nausea, vomiting, and pyrex-
ia. Rufinamide may induce potential arrhythmo-
genic risk since it does have a potential to shorten
QT interval (28). It appeared to have a favorable
cognitive profile (22). The new result from Phase IV
study showed a consistent and generally favorable
safety/tolerability profile of rufinamide used in rou-
tine clinical practice. Herein, the most frequently
reported adverse effects were somnolence and
decreased appetite (29). Moreover, it has been
shown that rufinamide in children aged less than
four years seems to be a safe and effective drug for
a broad range of seizures and epilepsy syndromes
(30).
Vigabatrin
Vigabatrin (vinyl-γ-aminobutyric acid) was
designed as an analog of γ-aminobutyric acid
(GABA). It is one of the newer anticonvulsant
drugs, however, it was already introduced in 1989,
but the Food and Drug Administration (FDA)
approved this drug for use in the United States in
2009. The mechanism of action is irreversible inhi-
bition of GABA-transaminase (GABA-T), which
causes the increase of GABA in CNS and thereby
vigabatrin inhibits excitatory processes that facili-
tate seizure activity (31). Vigabatrin is approved for
adjunct treatment in refractory complex partial
seizures in patients 10 years and older when all other
antiepileptic drugs used in combination treatment
are insufficient or poorly tolerated. Vigabatrin is
also used in monotherapy as the first-line treatment
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(next to adrenocorticotropic hormone, ACTH) in
infantile spasm (West syndrome) (32). 
The pharmacokinetic profile of vigabatrin
includes > 60% bioavailability, no biding with pro-
tein, a half-life of approximately 5-10 h, no metabo-
lism by cytochrome P450 enzyme and excretion by
the kidneys. Vigabatrin is a racemic mixture and
only S-enantiomers are active (3).
The most common adverse effects observed
during treatment with vigabatrin include
tiredness/fatigue, drowsiness, dizziness, depression,
and ataxia. Whereas, concentric bilateral visual field
deficit is the most serious adverse effect of vigaba-
trin and occurs in up to 30-45% of patients, and is
related to dose and duration of treatment (3, 33).
Moreover, numerous studies have reported magnet-
ic resonance imaging (MRI) signal abnormalities in
the basal ganglia and brainstem in children with
infantile spasm receiving vigabatrin (34, 35).
Nevertheless, despite these undesirable effects,
vigabatrin demonstrated indisputable efficacy
through randomized-controlled trials in patients
with infantile spasm. Thus, according to the expert
statement, the current benefit/risk ratio of vigabatrin
as first-line therapy is considered to be positive in
infantile spasms, given the severity of this epilepsy
and the lack of a safer optional therapy (36). 
Several studies have reported the efficacy of
vigabatrin in the treatment of focal seizures in pe-
diatric patients also with tuberous sclerosis complex
(TSC) etiology. The results suggest that patients
who start vigabatrin treatment at an earlier age may
have better seizure outcome. Moreover, a shorter
delay to treatment from seizure onset may also
improve seizure outcome (31).
Retigabine (Ezogabine)
Retigabine (N-(2-amino-4-(4-fluorobenzy-
lamino)-phenyl) carbamic acid) was approved in
Europe in 2011 and in the United States in 2010 as
an adjunctive treatment of drug-resistant focal
seizures with or without secondary generalization in
patients aged 18 years or older with epilepsy, where
other multiple alternative treatments have proved
inadequate or have not been tolerated. However, in
June 2017 the production of retigabine has been dis-
continued. Retigabine is a first-in-class voltage-
gated potassium channels opener. It stabilizes neu-
ronal potassium channels Kv7.2-7.5 (KCNQ2-
KCNQ5) in the open position, thereby causing
hyperpolarization and reduced firing of high-fre-
quency action potentials (37). It has been reported
that KCNQ2/Q3 channel mutations are connected
with neonatal epilepsy (38). An additional mecha-
nism of action involves selective positive modula-
tion of GABAA receptors, with preference for
extrasynaptic receptors (39). The pharmacokinetic
properties of retigabine include ~60% bioavailabili-
ty, ~80% protein bound, time to peak plasma con-
centration of 0.5-2 h, a half-life of 6-8 h, and elimi-
nation of ~84% of the dose by the kidneys.
Retigabine is partly metabolized to a less potent 
N-acetyl metabolite. It showed little or no potential
to inhibit cytochrome P450 isoenzymes (3, 40).
Ezogabine is dosed orally, 3 times daily at a maxi-
mum daily dose of 1200 mg. 
Several clinical trials have supported the effi-
cacy of retigabine. Adjunctive therapy with this
agent was generally well tolerated and reduced the
frequency of partial-onset seizures in a dose-
dependent manner (41-43). However, ezogabine has
shown a number of unique adverse effects. As it tar-
gets potassium channels in a non-selective way, not
only in the central nervous system, also in the
smooth muscle of the bladder, it may reduce the
contractility of the bladder smooth muscle, resulting
in urinary retention and dysuria. Furthermore, the
risk of retinal abnormalities, potential vision loss,
and blue-grey discoloration, most notably on or near
the lips, nails, and skin. In 2013 the FDA approved
changes to the drug label (a black boxed warning)
on the risks of abnormalities to the retina in the eye,
potential vision loss, and skin discoloration that may
become permanent. Retigabine may also prolong the
QT interval. Additional adverse effects, similar to
other anticonvulsant drugs include dizziness, som-
nolence, confusion, vertigo, fatigue, diplopia, hallu-
cinations, psychotic symptoms, and ataxia (37). 
Perampanel 
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Perampanel (2-(2-oxo-1-phenyl-5-pyridin-2-
yl-1,2-dihydropyridin-3-yl)benzonitrile) is a novel
AED approved in 2012 in Europe and the United
States. It is a first-in-class selective noncompetitive
antagonist at postsynaptic α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) gluta-
mate receptors. Through this mechanism of action,
perampanel reduces neuronal hyperexcitability and
seizure occurrence. Moreover, a competitive AMPA
receptor antagonist, selurampanel, is being studied
in epilepsy. Competitive and noncompetitive
AMPA receptor antagonists have similar profiles of
efficacy in animal seizure models although noncom-
petitive antagonists should have stronger anticon-
vulsant activity, due to the inability of high gluta-
mate levels, as seen in prolonged seizures, to over-
come their blocking action (44). It is approved for
adjunctive treatment of partial seizures with or with-
out secondary generalization in adults and adoles-
cents from the age of 12 years. Moreover, peram-
panel is approved as an adjunctive treatment for pri-
mary generalized tonic-clonic seizures in adults and
adolescents from the age of 12 years with idiopath-
ic, generalized epilepsy (45). Perampanel is avail-
able in an oral form with a maximum dose of 12 mg
once daily. The pharmacokinetic properties include
~100% bioavailability, time to peak plasma concen-
tration 0.5-2 h, 95% protein bound, half-life of 48-
105 h. Perampanel is extensively metabolized in the
liver by CYP3A4 to various inactive metabolites,
thus dose adjustments are needed in patients taking
anticonvulsant drugs that induce CYP3A4, like car-
bamazepine, oxcarbazepine, and phenytoin (46).
Common undesirable effects associated with peram-
panel treatment were somnolence, dizziness,
headache, fatigue, and irritability which were mild
in severity in the majority of patients and more fre-
quent at higher doses (47). Perampanel carries a
black box warning for serious or life-threatening
adverse effects, including aggression, hostility, irri-
tability, anger, and homicidal ideation, which were
the main reason of discontinuation of perampanel
treatment (48). Also recently, it has been reported
that perampanel was effective in particularly diffi-
cult-to-treat seizures in patients with cognitive
impairment, but the psychiatric adverse effect like
irritability, aggression, as well as suicidal idea-
tion/behavior occurred in 50% of patients and were
the most common reason of withdrawal (49). The
latest studies concern the use of perampanel in chil-
dren under 12. De Liso et al. have reported the effec-
tiveness and safety of adjunctive therapy with per-
ampanel in children and adolescents with refractory
epilepsy (50). The results have shown that peram-
panel was effective and exhibited a satisfactory tol-
erability profile. In another study, perampanel was
fairly effective in children and adolescents with very
refractory epilepsy, however, the rate of adverse
events leading to discontinuation was considerable
in this group (51).
Eslicarbazepine acetate
Eslicarbazepine acetate ((S)-10-acetoxy-10,11-
dihydro-5H-dibenzo/b,f/azepine-5-carboxamide),
like carbamazepine and oxcarbazepine, is a diben-
zazepine carboxamide analog, but it differs from
them in its molecular structure, which results in dif-
ferences in metabolism and pharmacology.
Eslicarbazepine acetate is a prodrug of the active
compound eslicarbazepine (S-licarbazepine), which
is the main entity responsible for the pharmacologi-
cal efficacy (52). Unlike carbamazepine, eslicar-
bazepine acetate is not metabolized to carba-
mazepine-10,11 epoxide, the active metabolite
mainly responsible for the adverse effects, and is not
susceptible to metabolic autoinduction.
The mechanism of action of eslicarbazepine
acetate is still being examined. It inhibits voltage-
gated sodium channels, especially in rapidly firing
neurons. However, it has a much lower affinity for
these channels in the resting state compared to car-
bamazepine and oxcarbazepine (53). On the other
hand, metabolite of eslicarbazepine acetate ñ esli-
carbazepine ñ like lacosamide reduces the availabi-
lity of voltage-gated sodium channels through
enhancement of slow inactivation, but lacosamide
demonstrated higher interaction with these channels
in the resting state, with fast inactivation gating and
shorter time to enter in the slow inactivated state.
Moreover, it has been found that eslicarbazepine
acetate inhibits T-type voltage-gated calcium chan-
nels (Cav3.2), in contrast to carbamazepine which
inhibits P/Q-type calcium channels (Cav2.1) (54).
Eslicarbazepine acetate was approved by the
European Medicines Agency (EMA) in 2009 and
the US Food and Drug Administration (FDA) in
2013 as adjunctive therapy in adults with refractory
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partial-onset seizures with or without secondary
generalization (52). Currently, in the EU it is
approved as adjunctive therapy in adults, adoles-
cents and children aged above 6 years, with partial-
onset seizures with or without secondary generaliza-
tion and as monotherapy in the treatment of partial-
onset seizures, with or without secondary generali-
zation, in adults with newly diagnosed epilepsy.
Eslicarbazepine acetate is available only in oral
form with a maximum daily dose of 1600 mg. It is a
one-daily anticonvulsant drug.
The pharmacokinetics are linear and dose-
dependent and include > 80% bioavailability, < 40%
protein bound, time to peak plasma concentration of
1-4 h, a half-life of 20-40 h, and elimination mostly
by kidneys. Eslicarbazepine acetate is a weak
inhibitor of CYP2C19 and a weak inducer of
CYP3A4, but only few drug-drug interactions have
been noticed (55).
Several studies have reported the efficacy of
eslicarbazepine acetate for focal seizures, also when
used as monotherapy (52, 56, 57). Most frequently
reported adverse effects were dizziness, somno-
lence, headache, diplopia, fatigue, and nausea. A
case report of an intentional overdose of eslicar-
bazepine acetate presenting with recurrent seizures,
hypoxemia and ventricular dysrhythmias has been
reported (58). Eslicarbazepine acetate has also been
examined for its utility in the treatment of bipolar
disorder, but it is not currently approved for this
condition (3).
Brivaracetam 
Brivaracetam (2S-2-([4R]-2-oxo-4-propy-
lpyrrolidinyl)-butanamide) is a selective, high-
affinity ligand of the synaptic vesicle protein 2A
(SV2A), which is located in presynaptic mem-
branes of all synaptic vesicles in the central nerv-
ous system and regulates the calcium-dependent
exocytosis of neurotransmitters into the synaptic
cleft. It has a binding affinity approximately 15- to
30-fold higher than levetiracetam, another SV2A
ligand, resulting in a dose approximately 10 times
lower. Recently, levetiracetam and brivaracetam
binding sites have been identified within the trans-
membrane hydrophilic core of SV2A (59). It has
been shown that the expression of SV2A protein is
significantly decreased during epileptogenesis sug-
gesting that the progression of epilepsy may be
influenced by this protein (44). Brivaracetam, in
contrast to levetiracetam, does not interact with
high voltage-gated calcium channels and with
AMPA receptors. 
Brivaracetam was approved in 2016 for
adjunctive treatment of focal (partial-onset)
seizures with or without secondary generalization
in patients from the age of 16 years. Currently, it is
approved in the United States also as monotherapy
treatment of focal seizures in adults. Dosage forms
include oral and intravenous formulations with a
maximum daily dose of 200 mg/kg, twice daily (3).
Furthermore, brivaracetam, like levetiracetam may
find an indication for generalized epilepsies, as
well as in progressive myoclonic epilepsies, which
is currently being examined and needs further stud-
ies (60, 61).
The pharmacokinetic profile of brivaracetam
is favorable and linear, with high oral bioavailabi-
lity, time to peak plasma concentration of 0.25-3 h,
very low protein binding, a half-life of approxi-
mately 8-9 h. The drug undergoes metabolism into
inactive compounds, mainly through the hydrolysis
of its acetamide group and to a lesser extent, via
hydroxylation involving the cytochrome P450
CYP2C19. Brivaracetam has not shown any signif-
icant effect on CYP3A4 activity. Moreover, it does
not significantly interact with other antiepileptic
drugs and more than 95% of it is excreted through
the urine, with an unchanged fraction of 8-11%
(60). The only noticeable interaction is a modest
increase in carbamazepine-epoxide when brivarac-
etam is co-administrated with carbamazepine (62,
63).
Efficacy of brivaracetam as an adjunctive
treatment in patients with refractory partial
seizures have been established in randomized,
placebo-controlled clinical trials and meta-analy-
ses. The safety profile of brivaracetam was favor-
able with mild to moderate undesirable effects that
usually do not affect the compliance to the treat-
ment. The most common adverse effects were
somnolence, fatigue, dizziness, and rarely irritabi-
lity (60, 64). As brivaracetam is a close analog of leve-
tiracetam, it would be interesting to know which of
them has better efficacy or tolerability for treating
patients with refractory partial seizures. It has been
recently reported that in patients with uncontrolled
seizures add-on therapy with levetiracetam might
have a slightly higher efficacy in comparison to
brivaracetam. Moreover, treatment with levetirac-
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etam was associated with a lower probability of
dizziness (65). However, as the authors stated that
several potentially confounding factors may have
contributed to or attenuated these findings, hence
further research is still needed. Additionally, it is
worthy to note that in brivaracetam showed
antiepileptogenic effects in kindling models in
mice and this effect was more pronounced than the
one obtained for levetiracetam (66). These evi-
dence indicated than SV2A ligands may exert not
only antiseizure activity but also antiepileptogenic
or disease-modifying activity (67).
Stiripentol
Stiripentol (4,4-dimethyl-1-[3,4(methylene-
dioxy)-phenyl]-1-penten-3-ol), is structurally unre-
lated to the other anticonvulsant drugs. As a result of
the presence of a chiral center at C-3, stiripentol is a
racemic mixture of two enantiomers (68). Although
Table 2. Summary of the third-generation anticonvulsant drugs.
Anticonvulsant Mechanism of Indications (types of Common side Serious side 
drug action seizures/syndromes) effects effects/overdose
Slow inactivation of Dizziness, Hypotension, PR and 
Lacosamide sodium channel/ Focal headache, diplopia, QRS prolongation, 
CRMP-2 biding nausea conduction abnormalities
Somnolence, Shortened QT interval, 
Focal, dizziness, headache, hematological 
Rufinamide
Sodium-channel
Lennox-Gastaut nausea and vomiting, abnormalities, life-blockade
syndrome tremor, anorexia, threatening rash, 
diplopia, fatigue suicidal ideation
Permanent vision loss, 
fatal hepatitis, 
Focal, Fatigue, drowsiness, encephalopathy and Vigabatrin ↑ GABA via GABA-T
West syndrome depression, ataxia coma, bradycardia, 
hypotension, status 
epilepticus
Dizziness, somnolence, 
confusion, fatigue 
dysarthria, paresthesia, Potential vision 
Retigabine/ ↑ K+ via potassium pigment changes loss, urinary 
ezogabine channels
Focal
(discoloration) of retention, cardiac 
ocular tissues, blue-grey arrhythmia
discoloration of the 
nails, lips and/or 
the skin
↓ glutamate via Focal, Dizziness, Aggression, psychosis, 
Perampanel AMPA receptor generalized somnolence, fatigue, homicidal/suicidal
antagonism tonic-clonic seizures ataxia, irritability ideation, stupor
Sodium-channel Dizziness, Hyponatremia, 
blockade/ somnolence, diplopia, cerebellar 
Eslicarbazepine Slow inactivation Focal headache, nausea syndrome, 
acetate of sodium and vomiting, ataxia, life-threatening rash, 
channel fatigue, insomnia PR prolongation
Dizziness, 
Brivaracetam Binds SV2A Focal somnolence, Severe somnolence
headache, fatigue
Drowsiness, ataxia, 
insomnia, nausea, 
Stiripentol
↑ GABA via GABA
Dravet syndrome loss of appetite, 
Neutropenia, 
A receptor
weight loss, hypotonia,
thrombocytopenia
dystonia
AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; CRMP-2, collapsing response mediator protein-2; GABA, gamma-
aminobutyric acid; GABA-T, GABA-transaminase; SV2A, synaptic vesicle 2A. * References in the text
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its mechanism of action has not been fully elucidat-
ed, evidence suggests an action of stiripentol on the
neurotransmission mediated by γ-aminobutyric acid
(GABA). More precisely, stiripentol potentiates
GABAeric neurotransmission by acting directly on
the GABAA receptors as a positive allosteric modu-
lator (69). Another postulated mechanism of action
may be inhibition of lactate dehydrogenase (LDH),
an enzyme that is best known as a marker of disease
and tissue injury (70). Recently, neuroprotective
properties of stiripentol, by reducing sodium- and
calcium-mediated neurotoxicity have been also
reported (71). Stiripentol was originally approved in
Europe in 2001 as an orphan drug for the treatment
of Dravetís syndrome (72). Currently, it is approved
for use in combination with clobazam and valproate
as adjunctive treatment of refractory generalized
tonic-clonic seizures in patients with severe
myoclonic epilepsy in infancy (Dravet syndrome)
whose seizures are not adequately controlled with
clobazam and valproate (36). The dose of stiripentol
is calculated on a mg/kg body weight basis and
divided into 2 or 3 doses.
The pharmacokinetic properties of stiripentol
include oral bioavailability = 90%, 99% protein
bound, time to peak plasma concentration of about
1-2 h, a half-life of 4.5-13 h, and elimination by the
kidneys. Because of its inhibition of several
cytochrome P450 enzymes, with high activity at
human CYP1A2, CYP3A4 and CYP2C19, it has
extensive pharmacokinetic interactions, including
phenobarbital, clobazam, carbamazepine, phenytoin
and valproate (73).
Results from clinical trials indicate that
stiripentol is significantly better than placebo with
regards to greater reduction in seizure frequency and
severity in the majority of cases (74-76). Common
adverse events have been related to a significant
increase in plasma concentrations of valproate and
clobazam after the addition of stiripentol. They
include drowsiness, ataxia, nausea, abdominal pain
and reduced appetite with weight loss. Also, neu-
tropenia was occasionally observed (77).
Furthermore, the efficacy of stiripentol as add-
on treatment for patients with focal refractory
epilepsy, as well as for the treatment of super-refrac-
tory status epilepticus have also been evaluated in
clinical trials (78, 79).
Selected compounds under clinical investigation
Ganaxolone
Ganaxolone (3α-hydroxy-3β-methyl-5α-preg-
nan-20-one) is a synthetic analog of allopreg-
nanolone. Like endogenous neurosteroids, it acts as
a positive allosteric modulator of GABAA receptors,
but without activation of progesterone receptors (80,
81). This agent exerts its inhibitory effect on neu-
ronal excitability in two ways: rapid phasic inhibi-
tion via synaptic GABAA receptors activation and
persistent or tonic inhibition through activation of
extrasynaptic GABAA receptors. Both these actions
occur at sites on the receptor complex that are dis-
tinct from those for benzodiazepines or barbiturates
(44). At the moment, ganaxolone is being developed
as an adjunctive therapy for the treatment of refrac-
tory focal seizures in adults. In the Phase II study
ganaxolone given 1500 mg/day in adults with
uncontrolled partial-onset seizures despite taking up
to three concomitant antiepileptic drugs (AEDs)
reduced seizures frequency and was generally safe
and well tolerated. Observed common adverse
events were mild to moderate in severity and includ-
ed dizziness, fatigue, and somnolence (82).
Moreover, the benefit from the use of ganaxolone
had been also examined in patients with infantile
spasms and continuing seizures. Ganaxolone was
able to reduce spasm frequency and was found to be
well tolerated with a good pharmacokinetic profile
(83, 84). Recently, it has been suggested by Yawno
et al. that ganaxolone may be an ideal antiseizure
drug for the treatment of neonatal seizures because
of its efficacy with a high safety profile and minimal
or no adverse effects on the neonatal brain (81).
Cannabidiol
Cannabidiol is a phytocannabinoid compound
derived from the cannabis plant. In contrast to
tetrahydrocannabinol, it does not appear to have
psychoactive effects. The mechanism of action is
unknown, as cannabidiol has a very low affinity for
the endocannabinoid receptors CB1 and CB2. A
number of proposed mechanisms of anticonvulsant
action of cannabidiol have been investigated and
include antagonism at G-coupled protein receptor
protein 55 (GPR55), blocking voltage-gated calcium
(T-type) and sodium channels, an agonist effect at
TRP channels, specifically in the TRPV1 channel,
modulation of adenosine (A1 and A2) receptors,
voltage-dependent anion-selective channel protein 1
(VDAC1), and tumour necrosis factor alpha
(TNFα), among others (85). Cannabidiol is a potent
inhibitor of CYP3A4, CYP2C19, and CYP2C9,
which can increase concentrations of several other
antiepileptic drugs (86). The results from an open-
label trial, in patients (aged 1-30 years) with severe,
intractable, childhood-onset, treatment-resistant
epilepsy have indicated that cannabidiol might
reduce seizure frequency. Most common adverse
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effects include somnolence, decreased appetite,
diarrhea, fatigue, convulsions, appetite changes, and
status epilepticus, which was the most common 
serious adverse event (87). Recently, it has been
reported in  Phase III clinical trial in children with
the Dravet syndrome, that a liquid formulation of
purified cannabidiol showed a greater reduction in
the median frequency of convulsive seizures per
month compared to placebo treatment. Adverse
events in the cannabidiol group included diarrhea,
vomiting, fatigue, pyrexia, somnolence, and abnor-
mal results on liver function tests (88). Currently,
cannabidiol has an orphan drug designation for
Dravet syndrome, infantile spasm, Lennox-Gastaut
syndrome, and tuberous sclerosis complex (87).
Selurampanel 
Selurampanel (N-[7-isopropyl-6-(2-methylpyr-
azol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methane-
sulfonamide) is a competitive antagonist of the
AMPA and kainate glutamate receptors. The dose-
dependent antiseizure effect of selurampanel has
been obtained in patients with photosensitive epilep-
sy (90). In the Phase II trial selurampanel (100 and
150 mg) was tested as add-on therapy to 1ñ3
antiepileptic drugs in patients with partial-onset
seizures. Results showed no statistically significant
doseñresponse relationship in selurampanel groups,
however, reductions in the total partial seizure fre-
quency over placebo were noted. Dizziness, somno-
lence, and fatigue were the most common adverse
events (91).
Everolimus
Everolimus (40-O-(2-hydroxyethyl)-rapamy-
cin) is a selective inhibitor of the mammalian/mech-
anistic target of rapamycin (mTOR) pathway. The
mTOR signaling pathway regulates cell growth, dif-
ferentiation, proliferation, and metabolism. How-
ever, hyperactivity of the mTOR pathway is associ-
ated with cellular alterations, including abnormal
differentiation, proliferation, and growth. It has been
found that inhibition of the mTOR pathway may
prevent epilepsy (92). Everolimus had been devel-
oped as an antitumor drug and then approved for the
treatment of several types of cancer (93). More
recently, it has been approved to treat pediatric and
adult patients with tuberous sclerosis complex
(TSC), which is associated with epilepsy. Seizures
are the most common neurological symptom of
tuberous sclerosis complex, occurring in 80% to
90% of affected patients and are often refractory to
antiepileptic treatment (93, 94). It has been reported
that mTOR dysregulation has been involved in sev-
eral genetic and acquired models of epileptogenesis.
In preclinical studies, mTOR inhibitors showed not
only an antiseizure activity but also an antiepilepto-
genic potential. The clinical reports support the
promising potential of everolimus in treating epilep-
sy in patients with TSC. In the phase III, random-
ized, double-blind, placebo-controlled study, eligi-
ble patients aged 2-65 years with tuberous sclerosis
complex and treatment-resistant seizures (≥ 16 in an
8-week baseline phase) receiving one to three con-
comitant antiepileptic drugs, everolimus treatment
significantly reduced seizure frequency with a toler-
able safety profile compared with placebo (95).
Adverse effects associated with the mTOR
inhibitors include infections of the upper respiratory
tract, aphthous ulcers, fatigue, rash, mucositis,
anorexia, gastrointestinal disorders, arthralgias,
thrombocytopenia, and effects on lipid metabolism
(96).
Moreover, other compounds with different
mechanisms of action are currently in phases I-III of
clinical development, namely adenosine, allopreg-
nanolone, bumetanide, cannabidivarin, 2-deoxy-D-
glucose, fenfluramine, huperzine A, minocycline,
SAGE-217, and valnoctamide. Furthermore, numer-
ous compounds or classes of compounds are inves-
tigated in preclinical studies, including bumetanide
derivatives, sec-butylpropylacetamide, FV-082,
1OP-2198, NAX 810-2, and SAGE-689, among
others (97).
Some limitations in pharmacotherapy of epilepsy
Although the administration of antiepileptic
drugs allows freedom from seizures in approximate-
ly 75% of patients with epilepsy, the occurrence of
adverse drug effects is still responsible for poor
compliance as well as the discontinuation of the
therapy in up to 25% of patients before having reached
the effective dose amount. Moreover, patients who
take a combination of AEDs are exposed to increased
risk of drug-drug interactions (55).
Psychiatric undesireable effects and suicidal
ideation/behavior after exposure to AEDs
It is worth to be highlighted that epilepsy, espe-
cially drug-resistant epilepsy, is associated with psy-
chiatric comorbidities including depression, psy-
choses and anxiety disorders. About 30% of patients
with newly diagnosed epilepsy and 50% of those
with drug-resistant epilepsy are considered to be
affected (98). The consequence of this is the fact that
suicide prevalence in patients with epilepsy is
approximately 2 times higher than that in the gener-
al population, occurring at a rate of about 12%.
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Moreover, suicide attempts occur in 5-30% of
patients with epilepsy compared to 1-7% in general
population (99). 
On the other hand, epilepsy treatment with
anticonvulsant drugs can negatively affect mood,
behavior and cognition. Recently, it has been report-
ed in a retrospective study that one or more neu-
ropsychiatric undesirable effects, including depres-
sion, aggression, irritable mood, anxiety, mood
instability, paranoid ideation, delusions, hallucina-
tions, and thought disorders, led to discontinuation
of the anticonvulsant drug in 1.9-16.7% of patients.
However, patients with pre-treatment psychiatric
conditions were statistically more likely to discon-
tinue the treatment with the new anticonvulsant drug
compared to patients who had no previous psychi-
atric history (98). It has been demonstrated that lev-
etiracetam, perampanel, and topiramate seem to be
associated with increased rates of irritability, hostil-
ity, and/or aggression, particularly in patients with a
previous history of psychiatric symptoms (100). As
mentioned above, perampanel carries a black box
warning for serious or life-threatening psychiatric
undesirable effects. No specific risk of aggression-
related behavior has been reported in adult patients
treated with carbamazepine, eslicarbazepine acetate,
gabapentin, lamotrigine, oxcarbazepine, and retiga-
bine. Similarly, children and adolescents who are
treated with levetiracetam, perampanel (especially
at higher doses), and topiramate, but also those tak-
ing gabapentin, sodium valproate, and zonisamide
should be monitored closely for possible aggressive
behaviors (100). 
Anticonvulsant drugs should also undergo
screening for suicidality during clinical studies and
post-marketing surveillance. Since 2008, after the
FDA issued an alert on an increased risk of suicide
ideation and behavior in people with epilepsy treat-
ed with AEDs, a number of studies on this issue
have been published (101). Among the first-genera-
tion drugs, phenobarbital has the highest risk of sui-
cidality (even up to 47%) and the rate is dose relat-
ed. Thus treatment with this drug should be avoided
in patients with depression or cognitive dysfunction
(99). Furthermore, it has been reported that some
first- and second-generation AEDs, including topi-
ramate, zonisamide, levetiracetam, tiagabine, and
felbamate may increase a risk of depression and sui-
cidal ideation. Less risks (< 1%) for depression have
been associated with phenytoin, valproate, carba-
mazepine, oxcarbazepine, gabapentin, pregabalin,
and lamotrigine (102). 
Amongst the third-generation, anticonvulsant
drugs, suicidal ideation and behavior have been
noted for rufinamide, retigabine, perampanel, viga-
batrin, brivaracetam, and lacosamide (37, 40, 47, 48,
103, 104). In the case of lacosamide, clinical trials
did not report a statistically significant increase in
depression and suicidal ideation (3). However, there
has been case report of sudden episode of depression
and suicidal ideation associated with the new onset
therapy with lacosamide (105). Two cases of suici-
dal ideation when rufinamide was used in the treat-
ment of refractory bipolar disorder have been report-
ed (106). Yates et al. have noted a serious suicidal
ideation and suicide attempt in one patient with
epilepsy receiving levetiracetam who switched to
brivaracetam (107). Huber and Schmid have report-
ed that in patients with highly drug-resistant epilep-
sy and cognitive impairment, perampanel showed
the highest rate of psychiatric adverse effects
amongst anticonvulsant drugs, such as irritability,
aggression, increased sensitivity, and suicidal
ideation/behavior, which occurred in 50% of the
patients and were the main reason to discontinue the
drug (49). The experts emphasized that psychiatric
adverse effects ranging from mild depression to
aggression and suicidal attempts should be especial-
ly monitored in patients treated with perampanel and
a history of psychiatric disorders (108). 
Summing up, experts from ILAE stressed that
suicidality in epilepsy is a multifactorial problem,
and although treatment with some AEDs can be
associated with suicidal ideation and behavior, the
actual risk is very low. Moreover, the risk of stop-
ping or even refusing to start AEDs is significantly
worse and can result in serious harm including death
of patient. Nevertheless, patients starting treatment
with AEDs or switching from one to another drug
should be advised to pay attention to any changes in
mood and suicidal ideation (101).
Drug-resistant epilepsy 
About 30% of epilepsy patients suffer from
uncontrolled seizures despite pharmacotherapy,
including the third-generation of anticonvulsant
drugs. The International League Against Epilepsy
Task Force proposed that ìdrug-resistant epilepsy
may be defined as failure of adequate trials of two
tolerated and appropriately chosen and used AED
schedules (whether as monotherapies or in combina-
tion) to achieve sustained seizure freedomî. Brodie
et al. have reported that out of a total group of 1098
patients with newly diagnosed epilepsy only 49.5%
of them remained seizure-free (i.e., not experiencing
seizures for at least 1 year) on their first AED, while
only 13.3, 3.7, 1.0, 0.4, 0.2, and 0.2% of the cohort
became seizure-free on the second, third, fourth,
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fifth, sixth or even seventh regimen (either as
monotherapy or in combination), respectively (109).
It is important to better understand these mecha-
nisms, as refractory epilepsy is especially associated
with increased morbidity and mortality, as well as
cognitive problems, serious psychosocial conse-
quences, and restricted quality of life. Recently, a
review which summarizes various theories that have
been proposed to clarify the mechanism(s) underly-
ing refractory epilepsy has been reported by Tang et
al. (110). Based on existing evidence the pharma-
coresistance in epilepsy is a multifactorial phenom-
enon and can include mechanisms such as:
● the transporter hypothesis (overexpression of
ABC transporters (especially P-glycoprotein) at
the blood-brain barrier, the multidrug resistance-
associated proteins ñ MRP or breast cancer resist-
ance proteins ñ BCRP ),
● the target hypothesis (changes in voltage-gated
ion channels and receptors, which resulted in
diminished drug sensitivity),
● the gene variant hypothesis (variations in genes
associated with AED pharmacokinetics and phar-
macodynamics cause inseparable pharmacoresis-
tance),
● the intrinsic severity hypothesis (common neuro-
biological factors which contribute to both epilep-
sy severity and pharmacoresistance),
● the neural network hypothesis (seizure-induced
degeneration and remodelling of the neural net-
work suppress the endogenous antiseizure system
and inhibit AEDs from accessing neuronal tar-
gets),
● the pharmacokinetic hypothesis (abnormalities in
AED plasma concentration range; overexpression
of efflux transporters in peripheral organs such as
intestine, liver or kidney; increased P-glycopro-
tein overexpression), 
Authors summarised that each of these refrac-
tory mechanisms has its own strengths and weak-
nesses and none of these theories alone sufficiently
explains pharmacoresistance in epilepsy.
Summary
Over the past few years, various anticonvulsant
drugs with new mechanisms of action were intro-
duced. The third-generation anticonvulsant drugs
have some therapeutic advantages relative to the
first- and the second-generation AEDs. The better
part of these AEDs, except for perampanel and esli-
carbazepine acetate, is that they are not metabolized
via cytochrome P450 enzymes thus resulting in less
drug-drug interactions. Most of the adverse effects
caused by third-generation drugs are dose-depend-
ent. However, all anticonvulsant drugs should be
screened for suicidal ideation or behavior.
Moreover, despite the availability of these new
drugs with favorable properties and new modes of
action a significant proportion of patients still con-
tinue to experience seizures and the problem of
refractory epilepsy still exists. Lastly, the anticon-
vulsant drugs work only symptomatically, currently
there is no drug that inhibits the processes of epilep-
togenesis. However, a better understanding of the
underlying mechanisms leading to epilepsy has per-
mitted to find new therapeutic strategies. A new
drug for seizure control is always welcome. 
Therefore, numerous preclinical and clinical
studies are still needed to be performed.
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